Can a capsule calm the Post-Meal stomach blues?

NCT ID NCT05199441

Completed Symptom relief Sponsor: Pusan National University Yangsan Hospital Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether a capsule called Galeo (dihydroxydibutylether) can ease the bloating, fullness, and nausea that some people feel after eating, a condition known as postprandial distress syndrome. About 226 adults with this condition will take either Galeo or a placebo for 4 weeks. Researchers will compare symptom changes to see if Galeo offers real relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dihydroxydibutylether (Galeo®), taken as a capsule before meals
What this could lead to: If it works, this could offer a new option for people with post-meal stomach discomfort, improving their daily quality of life.
What could go wrong: This is a phase 4 trial, but results may not apply to everyone. The treatment may not outperform placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSPEPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dyspepsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSPEPSIA

Contacts and locations

Locations

Chungnam National University Hospital

Daejeon, South Korea
Dong-A University Hospital

Busan, South Korea
Hallym University Sacred Heart Hospital

Anyang, South Korea
Korea University Guro Hospital

Seoul, South Korea
Koreal University Anam Hospital

Seoul, South Korea
Pusan National University Yangsan Hospital

Yangsan, Gyeungsangnam-do, 50612, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.